Alligator Bioscience expands pipeline: Preclinical development initiated for the candidate drug ATOR-1144
New candidate drug selected – the bispecific tumor-localizing CTLA-4 x GITR antibody ATOR-1144Lund, Sweden, October 30, 2018 – Alligator Bioscience AB (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, today announces that a new bispecific drug candidate, ATOR-1144, has entered preclinical development. ATOR-1144 is a first-in-class bispecific tumor-localized antibody targeting the checkpoint inhibitor CTLA-4 and the co-stimulatory receptor GITR. The bispecific antibody ATOR-1144 is a dual immune activator